Loading…
← CockpitCompetitor Analysis › GH Guardant Health, Inc.Open in the cockpit ↗

Guardant Health, Inc.GHCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Precision oncology company making liquid-biopsy blood tests for cancer screening, treatment selection and recurrence monitoring.

Momentum neutral 56
Mkt cap
$19.6B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$365M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-115.2 pp
WACC 12.8%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$145.14
1D+1.3%
1W-6.2%
1M-10.7%
3M-13.6%
6M+26.2%
YTD+42.1%
1Y+50.4%
ATR %6.5%
Beta1.33
52w lowhigh24.0% off high

What Guardant Health does

Precision oncology company making liquid-biopsy blood tests for cancer screening, treatment selection and recurrence monitoring.

Is paid per test: Medicare, insurers and patients pay for each blood sample analysed, while drug developers pay for tests used to select patients in trials. Guardant360, for advanced cancer, is the established earner; Shield, approved by the FDA in 2024 as a colorectal cancer screening test, is the newer line. The company is still loss-making.

Products and services

  • Guardant360 (advanced cancer genomic testing)
  • Guardant Reveal (recurrence monitoring)
  • Shield (blood-based colorectal cancer screening)

Customers

  • Oncologists
  • Biopharma companies (companion diagnostics/trials)
  • Health systems

Where it sits in the supply chain

  • Healthcare
  • Diagnostics/precision oncology
  • Liquid biopsy (cell-free DNA) cancer…

What could go right

  • Shield colorectal-screening reimbursement/adoption
  • Biopharma companion-diagnostics partnerships

What could go wrong

  • Reimbursement/coverage uncertainty for new tests
  • Competitive intensity in liquid biopsy

Moat: narrow (data, IP / patents, scale). Large proprietary genomic/clinical dataset and a first-mover position in liquid biopsy testing.

Headquarters: Palo Alto, California, USA · Founded: 2012 · Employees: 2,506

Named competitors

Guardant Health at a glance

Size Guardant Health (GH) is a United States Health Care company (Medical Specialties) with a market value of $19.6B, the 497th largest of 3,085 United States companies the cockpit tracks. Shares closed at $145.14 on 18 Nov 2026.

Performance Over six months the shares gained 26.2%, against +25.9% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 41.7% over the last twelve months (peer median +6.5%); the operating margin is -39.4% (peer median 17.4%).

Valuation It trades at 15.9× enterprise value to sales against a peer median of 6.0× (2nd most expensive of 21).

Capital Return on invested capital runs 115.2 points below its cost of capital (12.8% WACC).

Credit Guardant Health has 2 bonds outstanding ($1.09B).

Short interest Short interest is 7.0% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014016021 May 202621 Aug 202618 Nov 2026Peer median 124GH 123
Six months, rebased to 100: Guardant Health against the median of its 20 peers (local-currency closes).

Guardant Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.28B$982M$739M$564M$450M
Revenue growth—+33%+31%+25%—
Gross profit$834M$633M$449M$337M$292M
EBITDA-$464M-$397M-$401M-$520M-$499M
Net income-$485M-$416M-$436M-$479M-$655M
Free cash flow-$220M-$233M-$275M-$345M-$387M
Capital expenditure$58.7M$48.3M$35.1M$20.5M$77.5M
Total debt$1.69B$1.71B$1.34B$1.35B$1.37B

Quarterly statements and history in the cockpit →

Guardant Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%ZBHSOONSRTSTMNRVTYCOLO-B4543DIMSTE688271GKOSWSTLENSKARTBAX7733PENSNDXCMILMNBIMGH6-month return →1-month return →
Up and to the right = strong over both horizons. Guardant Health is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%5×10×15×ZBHSOONSRTSTMNCOLO-B4543DIM688271GKOSWSTLENSKARTBAX7733PENSNDXCMILMNBIMGHRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guardant Health is the large dot.

Guardant Health competitors and peer comparison

Head to head with its named competitors (GH vs NTRA vs GRAL vs TEM)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Guardant Health GH$19.6B+26%+42%-39%15.9×n/a
Natera NTRA$42.0B+41%+37%-9%14.1×n/a
GRAIL GRAL$4.59B+67%+17%-332%23.3×n/a
Tempus AI TEM$11.6B+39%+37%-18%8.2×n/a
Caris Life Sciences CAI$5.59B+24%+61%13%5.0×18.2%
Personalis PSNL$1.62B+88%+17%-157%18.2×n/a
Adaptive Biotechnologies ADPT$4.61B+104%+18%-16%15.8×n/a

How Guardant Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guardant Health against its 20 peers (data as of 18 Nov 2026)
MeasureGHPeer medianRank in peer set
1-month return-10.7%+5.7%2nd lowest of 21
6-month return+26.2%+25.9%10th highest of 21
Distance from 52-week high-24.0%-9.8%2nd lowest of 21
Revenue growth (TTM)+41.7%+6.5%2nd highest of 21
Operating margin-39.4%17.4%lowest of 21
EV / Sales15.9×6.0×2nd most expensive of 21
ROIC minus cost of capital-115.2 pp+2.2 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Guardant Health GHUnited States$19.6B+26%+42%-39%15.9×n/an/a
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%3.1×7.4%+3.2%
Sonova SOON.SWSwitzerland$19.8B+40%-6%23%4.9×6.0%+6.7%
Sartorius SRT.DEGermany$19.9B+26%+4%18%6.3×25.6%+8.7%
Straumann STMN.SWSwitzerland$20.4B+20%+2%21%6.6×16.2%+12.8%
Revvity RVTYUnited States$17.0B+61%+5%16%6.5×26.4%-5.5%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%4.6×-2.1%+8.3%
Terumo 4543.TJapan$24.0B+32%+15%17%3.1×8.8%+13.0%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%7.9×33.4%+9.2%
Steris STEUnited States$25.2B+21%+8%20%4.3×14.0%+13.8%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%6.0×n/an/a
Glaukos GKOSUnited States$13.8B+62%+47%-9%19.6×n/an/a
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%8.2×25.8%+7.4%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%12.4×53.2%+33.5%
Baxter International BAXUnited States$13.5B+39%+5%6%1.7×13.4%-0.7%
Olympus 7733.TJapan$12.7B+5%+9%18%2.0×-6.5%+6.7%
Penumbra PENUnited States$12.6B-2%+17%12%7.8×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%2.5×11.1%+5.6%
Dexcom DXCMUnited States$30.8B+16%+13%24%6.0×19.6%+19.3%
Illumina ILMNUnited States$31.8B+48%+6%21%7.2×27.2%+6.0%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%2.6×8.6%+5.5%

Guardant Health bonds and credit

Guardant Health has 2 bonds outstanding with $1.09B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Guardant Health's main competitors?
Named competitors: Exact Sciences (private or unlisted), Foundation Medicine (Roche) (private or unlisted), Natera (NTRA), GRAIL (GRAL), Tempus AI (TEM), Caris Life Sciences (CAI). The cockpit's measured peer set (industry) also includes Zimmer Biomet (ZBH), Sonova (SOON.SW), Sartorius (SRT.DE), Straumann (STMN.SW), Revvity (RVTY), Coloplast A/S (COLO-B.CO).
Is Guardant Health expensive compared with its peers?
On ev / sales it trades at 15.9× against a peer median of 6.0×, 2nd most expensive of 21 in its peer set.
How has Guardant Health stock performed?
Over six months to 18 Nov 2026 the shares returned +26.2% against +25.9% for the median peer; over one year +50.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.